LEADER 00807nam a2200241 i 4500 001 991003127719707536 005 20021205125909.0 008 021104s1995 sp ||| | spa 020 $a8420481726 035 $ab11758375-39ule_inst 035 $aLE01283147$9ExL 040 $aDip.to Lingue$bita 100 1 $aMunoz Molina, Antonio$0342437 245 14$aLas apariencias /$cAntonio Munoz Molina 260 $aMadrid :$bSantillana,$cc1995 300 $a270 p. ;$c22 cm. 490 0 $aTextos de Escritor 907 $a.b11758375$b27-04-17$c05-12-02 912 $a991003127719707536 945 $aLE012 868.64 MUN 3$g1$i2012000034495$lle012$o-$pE0.00$q-$rl$s- $t0$u1$v0$w1$x0$y.i12003426$z05-12-02 996 $aApariencias$9905003 997 $aUNISALENTO 998 $ale012$b01-01-02$cm$da $e-$fspa$gsp $h4$i1 LEADER 04120nam 22005775 450 001 9910350320203321 005 20250609110029.0 010 $a981-13-8906-3 024 7 $a10.1007/978-981-13-8906-1 035 $a(CKB)4100000009836957 035 $a(MiAaPQ)EBC5968658 035 $a(DE-He213)978-981-13-8906-1 035 $a(MiAaPQ)EBC5968253 035 $a(EXLCZ)994100000009836957 100 $a20191024d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Discovery in Japan $eInvestigating the Sources of Innovation /$fedited by Sadao Nagaoka 205 $a1st ed. 2019. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019. 215 $a1 online resource (xv, 333 pages) $cillustrations 300 $aIncludes index. 311 08$a981-13-8905-5 327 $aForeword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications. 330 $aThis book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices. 606 $aEconomic policy 606 $aManagement 606 $aIndustrial management 606 $aJapan?History 606 $aR & D/Technology Policy$3https://scigraph.springernature.com/ontologies/product-market-codes/W43000 606 $aInnovation/Technology Management$3https://scigraph.springernature.com/ontologies/product-market-codes/518000 606 $aHistory of Japan$3https://scigraph.springernature.com/ontologies/product-market-codes/715020 615 0$aEconomic policy. 615 0$aManagement. 615 0$aIndustrial management. 615 0$aJapan?History. 615 14$aR & D/Technology Policy. 615 24$aInnovation/Technology Management. 615 24$aHistory of Japan. 676 $a615.190941 702 $aNagaoka$b Sadao$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910350320203321 996 $aDrug Discovery in Japan$91939025 997 $aUNINA